BioXcel Therapeutics Inc Q1 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Guyn Kim - BMO Capital Markets Equity Research - Analyst : I was hoping you could review for us what you or could be -- what would be considered clinically meaningful in terms of reduction in the SERENITY trials. And when you look at the ADASUVE studies, you saw a slightly benefit in bipolar patients versus placebo than for schizophrenia. Is that something you also expect? Or is it just within normal variability for agitation studies?

Question: Guyn Kim - BMO Capital Markets Equity Research - Analyst : And do you still see a negative 3 point reduction in PEC score as the bar for clinically meaningful in either patient population? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. MAY 12, 2020 / 12:30PM, BTAI.OQ - Q1 2020 BioXcel Therapeutics Inc Earnings Call

Question: Guyn Kim - BMO Capital Markets Equity Research - Analyst : Great. And could you also speak to the rising cases in delirium in hospital ER settings due to COVID-19? And whether you should actually start looking at a 501 study in that setting now versus later?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : First one on 501, and then I have a follow-up on 701. So we've seen some developments on the competitive side in chronic management of agitation in Alzheimer's patients. How specifically do you expect to potentially bridge from acute treatment of 501 to the chronic management side, if that's possible? And on 701, we were encouraged to see your progress into the Phase II efficacy part of the trial for tNEPC in combination with KEYTRUDA, but could you give us a sense of what to expect in terms of the bar you might need to hit on efficacy? And how to potentially parse out single-agent activity of 701 versus activity of the combo?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Sure. So the question specifically was we've seen some developments on the competitive side on chronic management of agitation in Alzheimer's patients. You have a product right now that has -- is in development for acute agitation. How could that potentially be translated to maybe chronic management of agitation also in the longer run? without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its affiliated companies. MAY 12, 2020 / 12:30PM, BTAI.OQ - Q1 2020 BioXcel Therapeutics Inc Earnings Call

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : No, that's great.